South Korea · Delayed Price · Currency is KRW CTCBIO Statistics
Total Valuation
CTCBIO has a market cap or net worth of KRW 106.15 billion. The enterprise value is 126.58 billion.
| Market Cap | 106.15B |
| Enterprise Value | 126.58B |
Important Dates
The next estimated earnings date is Friday, March 20, 2026.
| Earnings Date | Mar 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTCBIO has 23.91 million shares outstanding. The number of shares has decreased by -0.21% in one year.
| Current Share Class | 23.91M |
| Shares Outstanding | 23.91M |
| Shares Change (YoY) | -0.21% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.32% |
| Float | 21.34M |
Valuation Ratios
The trailing PE ratio is 40.02.
| PE Ratio | 40.02 |
| Forward PE | n/a |
| PS Ratio | 0.80 |
| PB Ratio | 1.40 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | 10.46 |
| P/OCF Ratio | 9.44 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.33, with an EV/FCF ratio of 12.47.
| EV / Earnings | 47.92 |
| EV / Sales | 0.95 |
| EV / EBITDA | 10.33 |
| EV / EBIT | 22.78 |
| EV / FCF | 12.47 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.52.
| Current Ratio | 1.24 |
| Quick Ratio | 0.73 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 3.24 |
| Debt / FCF | 3.91 |
| Interest Coverage | 2.25 |
Financial Efficiency
Return on equity (ROE) is 3.49% and return on invested capital (ROIC) is 5.14%.
| Return on Equity (ROE) | 3.49% |
| Return on Assets (ROA) | 2.28% |
| Return on Invested Capital (ROIC) | 5.14% |
| Return on Capital Employed (ROCE) | 6.27% |
| Weighted Average Cost of Capital (WACC) | 4.15% |
| Revenue Per Employee | 535.32M |
| Profits Per Employee | 10.65M |
| Employee Count | 248 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 2.53 |
Taxes
In the past 12 months, CTCBIO has paid 445.16 million in taxes.
| Income Tax | 445.16M |
| Effective Tax Rate | 14.38% |
Stock Price Statistics
The stock price has decreased by -42.11% in the last 52 weeks. The beta is -0.10, so CTCBIO's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -42.11% |
| 50-Day Moving Average | 4,767.40 |
| 200-Day Moving Average | 6,001.68 |
| Relative Strength Index (RSI) | 43.78 |
| Average Volume (20 Days) | 73,419 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CTCBIO had revenue of KRW 132.76 billion and earned 2.64 billion in profits. Earnings per share was 110.61.
| Revenue | 132.76B |
| Gross Profit | 53.90B |
| Operating Income | 5.56B |
| Pretax Income | 3.09B |
| Net Income | 2.64B |
| EBITDA | 12.25B |
| EBIT | 5.56B |
| Earnings Per Share (EPS) | 110.61 |
Balance Sheet
The company has 23.44 billion in cash and 39.70 billion in debt, with a net cash position of -16.26 billion or -679.90 per share.
| Cash & Cash Equivalents | 23.44B |
| Total Debt | 39.70B |
| Net Cash | -16.26B |
| Net Cash Per Share | -679.90 |
| Equity (Book Value) | 75.92B |
| Book Value Per Share | 3,000.94 |
| Working Capital | 14.29B |
Cash Flow
In the last 12 months, operating cash flow was 11.25 billion and capital expenditures -1.10 billion, giving a free cash flow of 10.15 billion.
| Operating Cash Flow | 11.25B |
| Capital Expenditures | -1.10B |
| Free Cash Flow | 10.15B |
| FCF Per Share | 424.52 |
Margins
Gross margin is 40.60%, with operating and profit margins of 4.19% and 1.99%.
| Gross Margin | 40.60% |
| Operating Margin | 4.19% |
| Pretax Margin | 2.33% |
| Profit Margin | 1.99% |
| EBITDA Margin | 9.23% |
| EBIT Margin | 4.18% |
| FCF Margin | 7.65% |
Dividends & Yields
CTCBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.21% |
| Shareholder Yield | 0.21% |
| Earnings Yield | 2.49% |
| FCF Yield | 9.56% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 22, 2013. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 22, 2013 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
CTCBIO has an Altman Z-Score of 1.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 7 |